The Diagnostic Value of Thrombopoietin Level Measurements in Thrombocytopenia

Summary

It has been reported that blood trombopoietin (TPO) levels can discriminate between thrombocytopenia due to increased platelet destruction and decreased platelet production. With our TPO ELISA and a glycocalicin ELISA we analysed a large group of patients in detail and could confirm and amplify the above notion in detail.

TPO levels were determined in plasma from 178 clinically and serologically well-defined thrombocytopenic patients: 72 patients with idiopathic autoimmune thrombocytopenia (AITP), 29 patients with secondary AITP, 5 patients with amegakaryocytic thrombocytopenia and 72 patients who suffered from various diseases (46 in whom megakaryocyte deficiency was not and 26 in whom it was expected). In addition, we measured the level of glycocalicin as a marker of total body mass of platelets.

In all patients with primary AITP and secondary AITP, TPO levels were within the normal range or in some (n = 7) cases only slightly increased. The level of glycocalicin was not significantly different from that of the controls (n = 95). The patients with amegakaryocytic thrombocytopenia had strongly elevated TPO levels and significantly decreased glycocalicin levels. Similarly, among the 72 thrombocytopenic patients with various disorders, elevated TPO levels were only found in patients in whom platelet production was depressed. The mean level of glycocalicin in these patients was decreased compared to that in controls and patients with AITP, but was not as low as in patients with amegakaryocytic thrombocytopenia.

In conclusion, all patients with depressed platelet production had elevated levels of circulating TPO, whereas the TPO levels in patients with an immune-mediated thrombocytopenia were mostly within the normal range. Therefore, measurement of plasma TPO levels provides valuable diagnostic information for the analysis of thrombocytopenia in general.

Moreover, treatment with TPO may be an option in AITP.

• References

• 1 Tahara T, Usuki K, Sato H. et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders.. Br J Haematol 1996; 93: 783-8.
• 2 Emmons RV, Reid DM, Cohen RL. et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction.. Blood 1996; 87: 4068-71.
• 3 Kosugi S, Kurata Y, Tomiyama Y. et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura.. Br J Haematol 1996; 93: 704-6.
• 4 Folman CC, von dem Borne AEGK, Rensink IHJAM. et al. Sensitive measurement of thrombopoietin by a monoclonal antibody based sandwich enzyme-linked immunosorbent assay.. Thromb Haemost 1977; 78: 1262-7.
• 5 Steinberg MH, Kelton JG, Coller BS. Plasma glycocalicin: an aid in the classification of thrombocytopenic disorders.. N Engl J Med 1987; 317: 1037-42.
• 6 Beer JH, Büchi L, Steiner B. Glycocalicin: a new assay – the normal plasma levels and its potential usefulness in selected diseases.. Blood 1994; 83: 691-702.
• 7 Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia.. N Engl J Med 1993; 329: 1463-6.
• 8 Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3.. Blood 1996; 88: 429-36.
• 9 von dem Borne AEGK, Verheugt FWA, Oosterhof F, von Riesz E, Brutel de la Rivière A, Engelfriet CP. A simple immunofluorescence test for the detection of platelet antibodies.. Br J Haematol 1978; 39: 195-207.
• 10 Kiefel V, Santoso S, Weisheit M. Monoclonal antibody-specific immunobilization of platelet antigens (MAIPA): A new tool for the identification of platelet reactive antibodies.. Blood 1987; 70: 1722-6.
• 11 George JN, Woolf SH, Raskob GE. Thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology.. Blood 1996; 88: 3-40.
• 12 Gurney AL, Kuang WJ, Xie MH, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin.. Blood 1995; 85: 981-8.
• 13 Nagahisa H, Nagata Y, Ohnuki T. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation.. Blood 1996; 87: 1309-16.
• 14 McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count.. Blood 1995; 86: 3668-75.
• 15 Debili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets.. Blood 1995; 85: 391-401.
• 16 Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets.. Blood 1996; 87: 567-73.
• 17 Fielder PJ, Gurney AL, Stefanich E. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets.. Blood 1996; 87: 2154-61.
• 18 Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during Busulfan-induced thrombocytopenia in the rabbit.. Blood 1995; 85: 2720-30.
• 19 Heyns AP, Badenhorst PN, Lotter MG, Pieters H, Wessels P, Kotze HF. Platelet turnover and kinetics in immune thrombocytopenic purpura: Results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ.. Blood 1986; 67: 86-92.
• 20 Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura.. J Clin Invest 1987; 80: 33-40.
• 21 Siegel RS, Coleman RE, Kurlander R, Rosse WF. Platelet turnover: An important factor in predicting response to splenectomy in autoimmune thrombocytopenic purpura.. Blood 1984; 64: 873.
• 22 Ganser A, Ottmann OG, Erdmann H, Schulz G, Hoelzer D. The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia.. Ann Intern Med 1989; 111: 887-92.
• 23 Klumpp TR, Herman JH, Macdonald JS, Schnell MK, Mullaney M, Mangan KF. Autoimmune neutropenia following peripheral blood stem cell transplantation.. Am J Hematology 1992; 41: 215-7.
• 24 Stroncek DF, Shapiro RS, Filipovich AH, Plachta LB, Clay ME. Prolonged neutropenia resulting from antibodies to neutrophil-specific antigen NB1 following marrow transplantation.. Transfusion 1993; 33: 158-63.
• 25 Takahashi K, Taniguchi S, Akashi K. Human recombinant granulocyte colony-stimulating factor for the treatment of autoimmune neutropenia.. Acta Haematol 1991; 86: 95-8.
• 26 Taniguchi S, Shibuya T, Harada M, Niho Y. Decreased levels of myeloid progenitor cells associated with long-term administration of recombinant human granulocyte colony-stimulating factor in patients with autoimmune neutropenia.. Br J Haematology 1993; 83: 384-7.
• 27 Kuijpers TW, de Haas M, de Groot CJ, von dem Borne AEGK, Weening RS. The use of rh-G-CSF in chronic autoimmune neutropenia: reversal of autoimmune phenomena, a case history.. Br J Haematology 1996; 94: 464-9.
• 28 Vlasveld LT, de Haas M, Ermens AAM, Porcelijn L, van Marion-Kievit JA, von dem Borne AEGK. G-CSF-induced decrease of the anti-granulocyte autoantibody levels in a patient with autoimmune granulocytopenia.. Ann Haem. 1997 (in press).